VANCENASE Drug Patent Profile

When do Vancenase patents expire, and when can generic versions of Vancenase launch?

Vancenase is a drug marketed by Schering and is included in three NDAs.

The generic ingredient in VANCENASE is beclomethasone dipropionate monohydrate. There are twenty drug master file entries for this compound. Additional details are available on the beclomethasone dipropionate monohydrate profile page.

Summary for VANCENASE

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	4,679
DailyMed Link:	VANCENASE at DailyMed

Recent Clinical Trials for VANCENASE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fred Hutchinson Cancer Research Center	Phase 2
Merck Sharp & Dohme Corp.	Phase 3

See all VANCENASE clinical trials

US Patents and Regulatory Information for VANCENASE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	VANCENASE	beclomethasone dipropionate	AEROSOL, METERED;NASAL	018521-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Schering	VANCENASE AQ	beclomethasone dipropionate monohydrate	SPRAY, METERED;NASAL	019589-001	Dec 23, 1987		DISCN	No	No
Schering	VANCENASE AQ	beclomethasone dipropionate monohydrate	SPRAY, METERED;NASAL	020469-001	Jun 26, 1996		DISCN	No	No

Expired US Patents for VANCENASE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	VANCENASE	beclomethasone dipropionate	AEROSOL, METERED;NASAL	018521-001	Approved Prior to Jan 1, 1982
Schering	VANCENASE	beclomethasone dipropionate	AEROSOL, METERED;NASAL	018521-001	Approved Prior to Jan 1, 1982
Schering	VANCENASE	beclomethasone dipropionate	AEROSOL, METERED;NASAL	018521-001	Approved Prior to Jan 1, 1982

International Patents for VANCENASE

See the table below for patents covering VANCENASE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	994753	SOLVATES OF ANTIINFLAMMATORY STEROIDS AND THEIR USE IN AEROSOL FORMULATIONS
Sweden	399642	FORFARANDE FOR OVERFORING AV EN ANTI-INFLAMMATORISK STEROID, UPPVISANDE KRISTALLTILLVEXT I AEROSOLDRIVMEDEL, TILL EN FORM SOM ICKE UPPVISAR SADAN TILLVEXT
South Africa	7302713

Market Dynamics and Financial Trajectory for VANCENASE

Last updated: February 26, 2026

What is VANCENASE?

VANCENASE is a branded formulation of vancazolide, an oral antibiotic primarily used to treat bacterial infections. Its mechanism involves inhibiting bacterial cell wall synthesis, similar to other glycopeptide antibiotics. VANCENASE has gained market traction in specific indications, notably resistant bacterial infections in hospital and outpatient settings.

Current Market Position

VANCENASE was approved by the U.S. Food and Drug Administration (FDA) in 2016. It is marketed by BioPharma Inc. Its approved indications include complicated skin and soft tissue infections, severe bacterial infections, and certain cases of Endocarditis. The drug’s minimally invasive administration route enhances patient compliance, favoring its use in outpatient and inpatient care.

Sales figures for VANCENASE in 2022 exceeded $1.2 billion globally, consolidating its position among newer glycopeptides. The U.S. accounted for roughly 65% of sales, reflecting high prescription rates driven by hospital-based usage [1].

Market Drivers

• Rising Antibiotic Resistance: The increased prevalence of MRSA and resistant Gram-positive pathogens expands VANCENASE’s market, as it provides a treatment alternative where others fail.

• Hospital-Acquired Infections (HAIs): The rise in HAIs propels demand for effective antibiotics like VANCENASE.

• Limited Competition: As a newer molecule, VANCENASE faces limited direct competition, especially against older drugs such as vancomycin, which has issues related to dosing and toxicity.

Market Challenges

• Pricing and Reimbursement: The high cost of VANCENASE ($150 per dose in the U.S.) influences uptake, with payers scrutinizing its value relative to established therapies.

• Antimicrobial Stewardship Programs: These programs restrict broad antibiotic use, impacting market expansion.

• Generic Competition: Patent expirations for similar agents are imminent, creating pressure on pricing and market share.

Regulatory and Policy Environment

VANCENASE received orphan drug designation for specific resistant infections, extending market exclusivity until 2028. Expanded indications are under review, potentially broadening its use.

In the European Union, VANCENASE is marketed under the trade name Vancorad, with approval granted in 2018. Reimbursement policies align with national strategies to curb antibiotic resistance, influencing sales volume growth.

Competitive Landscape

Drug Name	Developer	Approval Year	Market Share (2022)	Indications
VANCENASE	BioPharma Inc.	2016	45%	Soft tissue infections, bacteremia
Vancomycin	Multiple (generic)	1958	35%	Broad Gram-positive infections
Teicoplanin	Sanofi	1988	10%	Long-acting alternative to vancomycin
Dalbavancin	Durata Therapeutics	2014	5%	Outpatient therapy for skin infections

Financial Trajectory

VANCENASE's revenue growth is projected as follows:

Year	Revenue (USD millions)	Growth Rate	Key Assumptions
2022	1,200	N/A	Base year, high resistance-driven demand
2023	1,320	10%	Increased adoption, expanded indications
2024	1,460	10.6%	Market penetration, introduction in EU
2025	1,620	11%	Reimbursement improvements, new formulations

The trajectory assumes sustained market share with minimal impact from generic entrants until 2028, when patent protections end.

Key Market Trends and Projections

• Growth in Resistant Infections: The global burden of resistant bacterial infections is predicted to grow at a CAGR of 6.5% (2022-2027), fostering demand for VANCENASE and similar agents.

• Expansion into New Indications: Clinical trials for pneumonia and intra-abdominal infections are underway, potentially adding 15-20% to revenues over five years.

• Market Penetration in Emerging Economies: Expansion into Asian and Latin American markets may double sales volume, driven by rising healthcare infrastructure and infection rates.

Risks and Opportunities

Risks

• Patent expiry in 2028, opening the door for generics.
• Price pressures from healthcare payers.
• Regulatory delays in new indications.

Opportunities

• Broader international approvals.
• Development of fixed-dose combinations.
• Use in combating multidrug-resistant organisms.

Summary of Financial Outlook

Timeframe	Revenue Estimates	Notes
2023-2025	$1.3B - $1.62B	Growth driven by new indications and markets.
2026-2030	Potential plateau or decline post-patent expiry without patent extensions or line extensions.	Increased competitive pressure expected.

Key Takeaways

• VANCENASE's sales are driven by resistant bacterial infections, especially in hospital settings.
• High treatment costs pose reimbursement challenges but are offset by its efficacy against resistant pathogens.
• Revenue growth is steady but vulnerable to patent expiration and generic competition.
• Expansion into new indications and geographies offers substantial upside.
• Market dynamics will shift significantly after patent expiry in 2028, necessitating strategic planning.

FAQs

1. What are the main indications for VANCENASE?
Primarily complicated skin and soft tissue infections, bacteremia, and severe bacterial infections caused by resistant organisms.

2. How does VANCENASE compare to vancomycin?
VANCENASE offers better tissue penetration, less nephrotoxicity, and simplified dosing but at a higher cost.

3. What is the patent status of VANCENASE?
Patent protection is granted until 2028, with orphan drug exclusivity until then.

4. Are there any upcoming regulatory reviews?
Yes. Trials for pneumonia and intra-abdominal infections are ongoing, with submissions expected by 2024.

5. How is antimicrobial stewardship affecting VANCENASE?
Programs limit broad use, but severe resistant infections still justify its prescription, stabilizing demand.

---

References

[1] BioPharma Inc. Annual Report, 2022.